When studies of AbbVie's chloesterol drug Niaspan raised questions about its effectiveness, analysts suggested it would lose its blockbuster status. But in the face of falling sales, AbbVie's former parent Abbott Laboratories simply raised the price.
In the fiercely competitive global stent market, Abbott seems to view size as mattering most.
After four years, patients with Abbott's MitraClip cardiac device required additional operations, and the benefits of the device were no better than those of traditional mitral valve surgery, a follow-up look at participants in company's pivotal EVEREST II trial concludes.
Resentment appears to be growing among multinational medical device companies over India's decision in February to slash reimbursement for drug-eluting stents.
Becton Dickinson will ally with a University of Pennsylvania spinout to develop a new blood diagnostic test that gauges heart attack and stroke risk for individual patients, bringing it into an increasingly competitive market space.
Johnson & Johnson, Abbott, St. Jude Medical and Quest Diagnostics are already experiencing new declines in demand for non-emergency medical devices and diagnostic tests. And that reality will likely spread to their competitors, Reuters reports. Blame the gradual ramp-up of the Affordable Care Act, which is likely to broaden the trend through much of the med tech industry in the months ahead.
The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene has partnered with the startup for development outside the U.S.
Abbott is adding to the springtime list of diabetes-related device recalls, this time for a line of its blood glucose meters the company sells in the United States.
With all of the FDA's safety worries about Abbott's MitraClip System very much in mind, a panel of experts gave a mixed endorsement for the product after a day-long hearing on March 20.
Abbott plans to slash more than 200 jobs from a plant in Ireland, the company disclosed this week, as it trims capacity from production for older-generation stent-related catheter products.